EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG

View source ↗

Summary

EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inflammatory bowel dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• Hukyndra (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Colitis, Ulcerative;Crohn Disease;Hidradenitis Suppurativa;Psoriasis;Spondylitis, Ankylosing;Uveitis. MAH: Stada Arzneimittel AG. Decision date: 15/07/2026